Почетна › Рак на дојка › Северна Каролина

Клинички испитувања за Рак на дојка во Северна Каролина

90 студии за Рак на дојка бараат учесници на локации во Северна Каролина.

Градови во Северна Каролина

Официјален текст на студијата (англиски)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Duke University, Durham

Се регрутираФаза 1/2

Возраст 12 и постари · Сите полови · Ажурирано 2.10.2026 · NCT04585750

Distance-Based Exercise to Preserve Function and Prevent Disability

Novant Health Cancer Institute - Kernersville, Kernersville
Novant Health Cancer Institute - Mount Airy, Mount Airy
Novant Health Forsyth Medical Center, Winston-Salem

Се регрутира

Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT07059884

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Duke Cancer Network, Durham
Cone Health Cancer Center, Greensboro

Се регрутираФаза 3

Возраст од 18 до 100 · Сите полови · Ажурирано 2.10.2026 · NCT05827081

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

AdventHealth Infusion Center Asheville, Asheville
Southeastern Medical Oncology Center-Clinton, Clinton
AdventHealth Infusion Center Haywood, Clyde
и уште 6

Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери

Возраст од 40 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT05334069

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Levine Cancer, Charlotte

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT07102381

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

University of North Carolina, Chapel Hill

Се регрутираФаза 2Добредојдени се здрави волонтери

Возраст од 18 до 45 · Жени · Ажурирано 1.10.2026 · NCT05557877

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06369285

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT07360314

Radiation Therapy and Thymus Function in Young Women With Breast Cancer

Duke Cancer Center, Durham

Се регрутираНабљудувачка студија

Возраст од 18 до 50 · Жени · Ажурирано 29.9.2026 · NCT07725172

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Duke Cancer Center, Durham

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT06120283

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Novant Health Cancer Institute ( Site 0019), Charlotte
Novant Health Oncology Specialists ( Site 0074), Winston-Salem

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07060807

Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians

University of North Carolina, Chapel Hill

Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери

Сите возрасти · Сите полови · Ажурирано 28.9.2026 · NCT05440929

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Carolinas Medical Center/Levine Cancer Institute, Charlotte

Се регрутира

Возраст 30 и постари · Жени · Ажурирано 25.9.2026 · NCT02945579

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Levine Cancer Institute ( Site 0014), Charlotte

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06312176

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Levine Cancer Institute, Albemarle
Levine Cancer Institute, Charlotte
Levine Cancer Institute, Charlotte
и уште 11

Се регрутираФаза 3

Возраст 60 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06377852

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Duke Cancer Institute, Durham

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07007559

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site, Charlotte
Clinical Trial Site, Durham

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT07085767

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Atrium Levine Cancer Institute, Charlotte

Се регрутира

Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT07214532

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Messino Cancer Centers, Asheville
WakeMed Cancer Care - Waverly Hematology & Medical Oncology, Cary
University of North Carolina Medical Center, Chapel Hill
и уште 1

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07174336

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

University of North Carolina Medical Center, Chapel Hill

Се регрутираФаза 2

Возраст 18 и постари · Жени · Ажурирано 22.9.2026 · NCT07287098

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Duke University Medical Center, Durham

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07213791

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Atrium Health, Charlotte

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 21.9.2026 · NCT05894239

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 18.9.2026 · NCT07340541

Identifying Patterns in the Breath of Individuals With Breast Cancer

Duke University Medical Cente, Durham

Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери

Возраст од 40 до 74 · Жени · Ажурирано 18.9.2026 · NCT06512350

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Oncology Specialists of Charlotte Pa, Charlotte
Carolina Oncology Specialists, Charlotte

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 17.9.2026 · NCT07173751

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 17.9.2026 · NCT07685938

Utility of a Mobile Application for Young Women With Breast Cancer

Atrium Health Levine Cancer, Charlotte

Се регрутира

Возраст од 18 до 45 · Жени · Ажурирано 15.9.2026 · NCT07009093

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Duke Cancer Institute, Durham
Cape Fear Valley Medical Center, Fayetteville
Cone Health Cancer Center at Wesley Long, Greensboro

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 15.9.2026 · NCT06492616

Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study

University of North Carolina at Chapel Hill, Chapel Hill

Се регрутираНабљудувачка студија

Возраст од 20 до 74 · Жени · Ажурирано 14.9.2026 · NCT07214610

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Research Site, Charlotte

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 11.9.2026 · NCT05123482

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

Duke Cancer Institute, Durham

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 10.9.2026 · NCT03424005

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Duke Cancer Institute, Durham

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT06253871

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Levine Cancer Institute, Charlotte
Novant Health Cancer Institute, Charlotte
Novant Health Oncology Specialists, Winston-Salem

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT07100106

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Duke Cancer Institute, Durham

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 4.9.2026 · NCT05315700

Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)

University of North Carolina, Chapel Hill

Се регрутираФаза 2

Возраст 50 и постари · Жени · Ажурирано 3.9.2026 · NCT06902311

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

Duke University, Durham

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT05846789

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Novant Health Cancer Institute, Charlotte
Duke Cancer Institute, Durham
Novant Health Cancer Institute, Winston-Salem

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT06790693

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

Се регрутираДобредојдени се здрави волонтери

Возраст 18 и постари · Сите полови · Ажурирано 2.9.2026 · NCT07025785

The Vanguard Study: Testing a New Way to Screen for Cancer

UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Durham VA Medical Center, Durham

Се регрутираДобредојдени се здрави волонтери

Возраст од 45 до 75 · Сите полови · Ажурирано 2.9.2026 · NCT06995898

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Atrium Health Stanly/LCI-Albemarle, Albemarle
Cone Health MedCenter Asheboro, Asheboro
Cone Health Cancer Center at Alamance Regional, Burlington
и уште 47

Се регрутираФаза 3

Возраст од 18 до 60 · Жени · Ажурирано 2.9.2026 · NCT05879926

Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.